Back to Stocks

NPHC

NUTRA PHARMA CORP
1 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Nutra Pharma is attempting a strategic transformation from a speculative biotech entity into a commercially viable pharmaceutical provider.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

The financial reality for Nutra Pharma is stark, characterized by a precarious balance sheet and a history of regulatory failure.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every NPHC filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The 10-K filing reveals a company at a crossroads, balancing a promising intellectual property moat against an existential financial crisis. While the shift toward in-house manufacturing and the pursuit of Orphan Drug status provide a theoretical path to exponential growth, the immediate priority is survival. The company is currently relying on convertible debt and loans from officers to fund basic operations, creating a high risk of massive shareholder dilution. Investors are essentially betting on a binary outcome: either the company can successfully scale its OTC product line and secure new financing to reach its 2026 clinical milestones, or it will succumb to its mounting debt obligations and liquidity shortages. The transition to a more transparent reporting cadence and the settlement of legacy lawsuits are positive steps, but they do not offset the fundamental instability of the balance sheet.

Selected Quarter

Core Takeaway

Nutra Pharma has a viable product line and a rare FDA designation, but is nearly insolvent with a massive debt load.

Investor Lens

The trade-off is between the potential of a rare-disease breakthrough and the immediate risk of bankruptcy.

Watch Next

The initiation of Pediatric MS Phase I/II trials and any new equity financing rounds in 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.28Q2 '26 (10-K)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-K)
bearishMay 20

Gross margin fell from 63.07% in 2024 to 51.03% in 2025.

margin compression
60%
bearishMay 20

Heavy reliance on convertible notes with very low conversion prices.

dilution risk
90%
neutralMay 20

Settlement of SEC lawsuit involving disgorgement and civil penalties.

regulatory action
50%
bullishMay 20

Raised $1.05M through convertible notes to fund operations.

capital raise
40%

Filing History

10-KMay 20, 2026
Expand Sequence

The 10-K filing reveals a company at a crossroads, balancing a promising intellectual property moat against an existential financial crisis. While the shift toward in-house manufacturing and the pursuit of Orphan Drug status provide a theoretical path to exponential growth, the immediate priority is survival. The company is currently relying on convertible debt and loans from officers to fund basic operations, creating a high risk of massive shareholder dilution. Investors are essentially betting on a binary outcome: either the company can successfully scale its OTC product line and secure new financing to reach its 2026 clinical milestones, or it will succumb to its mounting debt obligations and liquidity shortages. The transition to a more transparent reporting cadence and the settlement of legacy lawsuits are positive steps, but they do not offset the fundamental instability of the balance sheet.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.